May 3, 2018 

Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://newfdaapprovals.com 

1:29 TRINTELLIX® (vortioxetine) prescribing information now includes new data showing improvement in processing speed, an important aspect of cognitive function in acute major depressive disorder (MDD) https://www.prnewswire.com/news-releases/trintellix-vortioxetine-prescribing-information-now-includes-new-data-showing-improvement-in-processing-speed-an-important-aspect-of-cognitive-function-in-acute-major-depressive-disorder-mdd-300641565.html

3:38 Bausch + Lomb ULTRA® contact lenses receive FDA approval for extended wear indication https://www.prnewswire.com/news-releases/bausch--lomb-ultra-contact-lenses-receive-fda-approval-for-extended-wear-indication-300641046.html

4:45 Paradigm Spine receives FDA pre-market approval (PMA) for first of its kind disposable instrument kit https://www.prnewswire.com/news-releases/paradigm-spine-receives-fda-pre-market-approval-pma-for-first-of-its-kind-disposable-instrument-kit-300640578.html

6:55 REGENXBIO receives FDA fast track designation for RGX-121 gene therapy for the treatment of mucopolysaccharidosis type II https://www.prnewswire.com/news-releases/regenxbio-receives-fda-fast-track-designation-for-rgx-121-gene-therapy-for-the-treatment-of-mucopolysaccharidosis-type-ii-300640370.html 

Brought to you by Nascent Medical. For assistance with medical writing, please email [email protected].

Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/